Sexual health in breast cancer: updated data from pharmacological and non-pharmacological interventions
Two studies provide new insights on the effects of vaginal oestrogen therapy and physical exercise to tackle sexual impairment
Good tolerability of datopotamab deruxtecan supports its place in the treatment of HR+/HER2− breast cancer
In the TROPION-Breast01 trial, adverse events of special interest were generally low grade, easily managed and did not compromise scheduled treatment
Pregnancy after breast cancer: study provides reassurance to BRCA carriers undergoing assisted reproductive techniques
No difference in risk recurrence or pregnancy outcomes was reported between young women with BRCA1 or BRCA2 mutations conceiving naturally and those using fertility treatments
Atezolizumab does not improve prognosis in early relapsing advanced triple-negative breast cancer
However, a higher objective response rate with atezolizumab was reported in the IMpassion132 trial suggesting that at least some patients could benefit from it
The growing role of AI in breast cancer
The rapidly increasing integration of AI into many aspects of breast cancer management calls for urgent definition of expected levels of evidence and bespoke regulatory and reimbursement processes
Prolonged use of adjuvant imatinib shows promise in localised GIST
A study reports a disease-free survival benefit with six years of maintenance therapy with imatinib compared to the 3-year standard of care
Fuzuloparib prolongs progression-free survival in HER2 negative metastatic breast cancer
A benefit was observed in women with germline BRCA1/2 mutations when treated with the PARP inhibitor alone or in combination with apatinib
Adjuvant immunotherapy improves overall survival in renal-cell carcinoma
Updated results from the KEYNOTE-564 trial confirm the role of pembrolizumab after surgery
Adjuvant alectinib has been approved by the FDA for resected ALK-positive NSCLC
The tyrosine kinase inhibitor showed to prolong disease-free survival as compared to chemotherapy and clinically meaningful benefit with respect to CNS disease–free survival
Liquid biopsy: may ctDNA tumour fraction help interpret negative results?
A study illustrates a methodology that shows promise to distinguish true negative liquid biopsy results from indeterminate results that may benefit from follow-up tissue testing